Edition 1 / March 2020
Welcome to the first edition of Corden Connect in 2020! With the first quarter off to a good start, I would like to begin by saying thank you, our existing & new customers, for all the collaboration, ongoing trust and loyalty you showed us in 2019!
I can ensure you the CordenPharma team is inspired by the direct impact you have on patients, and as such we strive for excellence every day to deliver on-time, high quality products with integrity, transparency and flexibility. This is our vision – the yardstick by which we measure our progress and efforts of continuous improvement.
Looking back on 2019, I want to provide you with an update on CordenPharma’s financial performance. We realized a continued growth trajectory and experienced a strong net sales increase of €75 million (+24.2%), which resulted in total sales of €386 million. Sales grew favorably across our integrated network of facilities due to the strong demand for new projects and commercial product launches.
Although DCAT Week 2020 was unfortunately canceled due to concerns around COVID-19, the CordenPharma team will be reaching out to each customer individually to transfer the originally scheduled face-to-face meetings into video or teleconference calls. Feel free to reach out to your respective Key Account Managers or Platform Managers if you have any further questions.
As we embark on this new year and decade, we aim to focus our growth on four key Technology Platforms: Highly Potent & Oncology, Peptides, Lipids & Carbohydrates, Small Molecules, and Injectables. In addition, we will strengthen our Fully Integrated Supply Solutions (API Starting Materials > Intermediates > APIs > Drug Products > Packaging) to bring you the maximum benefit for this increased demand. How will we do this?
CordenPharma’s mission is founded on four Pillars of success that will guide us to support you in 2020 & beyond:
While applying these four pillars to our daily business decisions in 2020, our key topics for improvement to ensure your overall customer satisfaction remain Delivery In Full On Time (DIFOT), Right First Time and Project Management. As it relates to the latter, I encourage you to read Mike Ironside’s article on CordenPharma’s Global Project Management Team, as it will be key to your multi-site projects and an area where we continue to put great emphasis.
As always, we would be delighted to receive any feedback through your Key Account Manager on how you believe we can better serve you in the future! We look forward to a successful 2020 and new decade.
Dr. Michael Quirmbach
CEO & President, CordenPharma
Stay up to date with the latest thought leadership articles and news from CordenPharma.